Key result
Angiotensin receptor blockers and other renin-angiotensin system acting antihypertensives showed a tendency to be superior to other antihypertensive classes in preventing the progression to Alzheimer's disease.
Why the study?
Alzheimer disease, dementia, and hypertension are highly prevalent, leading to speculation that angiotensin receptor blockers may be neuroprotective against Alzheimer disease.
Do angiotensin receptor blockers reduce the incidence of dementia in hypertensive adults compared to other antihypertensive drugs?
Systematic Review (n=4,070)
Do angiotensin receptor blockers reduce the incidence of dementia in hypertensive adults compared to other antihypertensive drugs?
This systematic review suggests that angiotensin receptor blockers may provide superior neuroprotection against Alzheimer's disease compared to other antihypertensive agents.
May support ARB preference over other antihypertensives for dementia prevention in MCI; leaves open need for confirmatory RCTs.
Alzheimer's disease (AD) and dementia are preventable and highly prevalent diseases, as is systemic arterial hypertension. Thus, it is speculated that angiotensin receptor blockers (ARBs) may be neuroprotective against AD. Objective: The aim of this study was to evaluate if the use of ARBs confers a neuroprotective effect on AD, through a systematic review. Methods: Studies published on Embase, LILACS, SciELO, and PubMed were evaluated. The selection of the studies included those that evaluated the use of antihypertensive drugs in individuals with a previous diagnosis of mild cognitive impairment. The data were extracted with the Cochrane Effective Practice and Organization of Care (EPOC) form. The risk of bias was evaluated by the EPOC "Risk of bias tool." Results: A total of 12 articles were identified, and 3 articles were selected. Two of them analyzed the use of ARB/ACEI versus other antihypertensives and the development of dementia. Conclusion: There is a tendency for ARBs to be superior to other antihypertensives in preventing dementia.
No takes yet. Share an insight, caveat, or question.
Müller et al. (2023) conducted a systematic review in Mild cognitive impairment and hypertension (n=4,070). Angiotensin receptor blockers (ARBs) and ACE inhibitors vs. Other antihypertensives (beta-blockers, diuretics, calcium channel blockers) or placebo was evaluated on Incidence of dementia or Alzheimer's disease. Angiotensin receptor blockers and other renin-angiotensin system acting antihypertensives showed a tendency to be superior to other antihypertensive classes in preventing the progression to Alzheimer's disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: